UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Behandlung der Acne fulminans mit Tumornekrosefaktor‐α‐Inhibitoren – eine Übersicht klinischer Fälle und der Literatur

Journal der Deutschen Dermatologischen Gesellschaft, 2024-01, Vol.22 (1), p.23-28

2024

Volltextzugriff (PDF)

Leishmaniasis in immunosuppressed individuals

Clinical microbiology and infection, 2014-04, Vol.20 (4), p.286-299

2014

Volltextzugriff (PDF)

Outcome of pregnancy in women with inflammatory bowel disease treated with antitumor necrosis factor therapy

Inflammatory bowel diseases, 2011-09, Vol.17 (9), p.1846-1854

2011

Volltextzugriff (PDF)

High-dose, high-frequency infliximab: A novel treatment paradigm for hidradenitis suppurativa

Journal of the American Academy of Dermatology, 2020-05, Vol.82 (5), p.1094-1101

2020

Volltextzugriff (PDF)

Trough Concentration Response in Infliximab and Adalimumab Treated Children With Inflammatory Bowel Disease Following Treatment Adjustment

Journal of pediatric gastroenterology and nutrition, 2023-05, Vol.76 (5), p.576-581

2023

Volltextzugriff (PDF)

An intriguing case of hepatosplenic lesions and pneumonia during anti-TNF therapy for IBD

Gastroenterology (New York, N.Y. 1943), 2024-11

2024

Volltextzugriff (PDF)

Appropriate Therapeutic Drug Monitoring of Biologic Agents for Patients With Inflammatory Bowel Diseases

Clinical gastroenterology and hepatology, 2019-08, Vol.17 (9), p.1655-1668.e3

2019

Volltextzugriff (PDF)

Disseminated tuberculosis after anti-TNF alpha treatment: Do not blindly trust the IGRA test

Enfermedades infecciosas y microbiologia clinica (English ed.), 2024-02, Vol.42 (2), p.98-101

2024

Volltextzugriff (PDF)

Safety of anti-tumor necrosis factor therapy in inflammatory bowel disease

World journal of gastroenterology : WJG, 2009-05, Vol.15 (17), p.2067-2073

2009

Volltextzugriff (PDF)

Increased arterial stiffness in Crohn's disease: Prevalence, associated factors and impact of anti-TNF therapy

Gastroenterología y hepatología, 2024-09, p.502252, Article 502252

2024

Volltextzugriff (PDF)

Atteinte médullaire de la sarcoïdose : facteurs pronostiques et efficacité des traitements

Revue neurologique, 2022-04, Vol.178, p.S108-S108

2022

Volltextzugriff (PDF)

Safety of Vedolizumab and Ustekinumab Compared With Anti-TNF in Pregnant Women With Inflammatory Bowel Disease

Clinical gastroenterology and hepatology, 2024-01

2024

Volltextzugriff (PDF)

Anti-TNF Therapy in Spondyloarthritis and Related Diseases, Impact on the Immune System and Prediction of Treatment Responses

Frontiers in immunology, 2019-03, Vol.10, p.382-382

2019

Volltextzugriff (PDF)

Progression of Inflammatory Bowel Diseases Throughout Latin America and the Caribbean: A Systematic Review

Clinical gastroenterology and hepatology, 2020-02, Vol.18 (2), p.304-312

2020

Volltextzugriff (PDF)

TNF inhibition in vasculitis management in adenosine deaminase 2 deficiency (DADA2)

Journal of allergy and clinical immunology, 2022-05, Vol.149 (5), p.1812-1816.e6

2022

Volltextzugriff (PDF)

Longterm Safety and Efficacy of Adalimumab and Infliximab for Uveitis Associated with Juvenile Idiopathic Arthritis

Journal of rheumatology, 2018-08, Vol.45 (8), p.1167-1172

2018

Volltextzugriff (PDF)

A first‐in‐human study of the novel immunology antibody–drug conjugate, ABBV‐3373, in healthy participants

British journal of clinical pharmacology, 2024-01, Vol.90 (1), p.189-199

2024

Volltextzugriff (PDF)

A randomised double-blind placebo-controlled crossover trial of HUMira (adalimumab) for erosive hand OsteoaRthritis – the HUMOR trial

Osteoarthritis and cartilage, 2018-07, Vol.26 (7), p.880-887

2018

Volltextzugriff (PDF)

Risk of anti-TNF therapy on pregnancy, breastfeeding, live vaccines and related information in patients with inflammatory bowel disease: Real-world data from a nationwide study

Digestive and liver disease, 2024-07

2024

Volltextzugriff (PDF)

Molecular mechanisms of action of anti-TNF-α agents – Comparison among therapeutic TNF-α antagonists

Cytokine (Philadelphia, Pa.), 2018-01, Vol.101, p.56-63

2018

Volltextzugriff (PDF)

Population Pharmacokinetics of Ozoralizumab in Patients with Rheumatoid Arthritis

Journal of clinical pharmacology, 2024-04, Vol.64 (4), p.418-427

2024

Volltextzugriff (PDF)

Antiphospholipid syndrome autoantibodies induction after treatment with anti-TNF alpha therapy in patients with IBD

Gastroenterología y hepatología, 2024-09, p.502258, Article 502258

2024

Volltextzugriff (PDF)

Disseminated tuberculosis after anti-TNF alpha treatment: Do not blindly trust the IGRA test

Enfermedades infecciosas y microbiología clínica, 2024-02, Vol.42 (2), p.98-101

2024

Volltextzugriff (PDF)

Certolizumab pegol for the treatment of chronic plaque psoriasis: Results through 48 weeks from 2 phase 3, multicenter, randomized, double-blinded, placebo-controlled studies (CIMPASI-1 and CIMPASI-2)

Journal of the American Academy of Dermatology, 2018-08, Vol.79 (2), p.302-314.e6

2018

Volltextzugriff (PDF)

Facteurs associés à la rémission sans traitement à 5 ans dans la spondylarthrite axiale débutante : données de la cohorte DESIR

Revue du rhumatisme (Ed. française : 1993), 2022-10, Vol.89 (5), p.497-502

2022

Volltextzugriff (PDF)

1 – 25 von 4.292

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(3.722)
Mit Volltextzugriff
(3.410)

Publikationsform

2 weitere anzeigen...

Weniger anzeigen...

Sprache

8 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

Science & Technology
(3.098)
Life Sciences & Biomedicine
(3.079)
Humans
(2.250)
Anti-Tnf
(1.491)
Female
(1.239)
Male
(1.180)
Tumor Necrosis Factor-Alpha - Antagonists & Inhibitors
(1.151)
Rheumatology
(1.011)
Adult
(933)
Middle Aged
(911)
Infliximab
(900)
Rheumatoid Arthritis
(894)
Gastroenterology & Hepatology
(711)
Adalimumab
(710)
Treatment Outcome
(688)
Inflammatory Bowel Disease
(632)
Antirheumatic Agents - Therapeutic Use
(570)
Arthritis, Rheumatoid - Drug Therapy
(553)
Antibodies, Monoclonal - Therapeutic Use
(529)
Crohn's Disease
(509)

15 weitere anzeigen...

Weniger anzeigen...

Kollektion

MEDLINE
(2.342)
Connected Ingenta
(2.231)
EZB-FREE-00999 freely available EZB journals
(1.489)
Journals@Ovid
(1.404)
Access via ScienceDirect (Elsevier)
(1.148)
IngentaConnect Journals
(733)
SpringerNature Journals
(560)
Access via Oxford University Press
(478)
Access via Taylor & Francis
(469)
Access via Wiley Online Library
(434)
Taylor & Francis Current Content Access
(431)
Oxford Journals 2020 Medicine
(407)
EZB-NALI2-00462 Springer Archive NL
(364)
Access via Taylor & Francis
(323)
EZB-NALI5-00465 Elsevier Archive NL
(291)
Single Journals
(264)
Wiley Online Library Full Collection 2018
(223)
BMJ Journals
(197)
EZB-NALGM-00452 BMJ Journals Archive NL
(159)
Ebook Central Perpetual and DDA
(103)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(18)
... seit 30 Tagen
(4)

Menü

Weitere Dienste

Einstellungen

Behandlung der Acne fulminans mit Tumornekrosefaktor‐α‐Inhibitoren – eine Übersicht klinischer Fälle und der Literatur

Leishmaniasis in immunosuppressed individuals

Outcome of pregnancy in women with inflammatory bowel disease treated with antitumor necrosis factor therapy

High-dose, high-frequency infliximab: A novel treatment paradigm for hidradenitis suppurativa

Trough Concentration Response in Infliximab and Adalimumab Treated Children With Inflammatory Bowel Disease Following Treatment Adjustment

An intriguing case of hepatosplenic lesions and pneumonia during anti-TNF therapy for IBD

Appropriate Therapeutic Drug Monitoring of Biologic Agents for Patients With Inflammatory Bowel Diseases

Disseminated tuberculosis after anti-TNF alpha treatment: Do not blindly trust the IGRA test

Safety of anti-tumor necrosis factor therapy in inflammatory bowel disease

Increased arterial stiffness in Crohn's disease: Prevalence, associated factors and impact of anti-TNF therapy

Atteinte médullaire de la sarcoïdose : facteurs pronostiques et efficacité des traitements

Safety of Vedolizumab and Ustekinumab Compared With Anti-TNF in Pregnant Women With Inflammatory Bowel Disease

Anti-TNF Therapy in Spondyloarthritis and Related Diseases, Impact on the Immune System and Prediction of Treatment Responses

Progression of Inflammatory Bowel Diseases Throughout Latin America and the Caribbean: A Systematic Review

TNF inhibition in vasculitis management in adenosine deaminase 2 deficiency (DADA2)

Longterm Safety and Efficacy of Adalimumab and Infliximab for Uveitis Associated with Juvenile Idiopathic Arthritis

A first‐in‐human study of the novel immunology antibody–drug conjugate, ABBV‐3373, in healthy participants

A randomised double-blind placebo-controlled crossover trial of HUMira (adalimumab) for erosive hand OsteoaRthritis – the HUMOR trial

Risk of anti-TNF therapy on pregnancy, breastfeeding, live vaccines and related information in patients with inflammatory bowel disease: Real-world data from a nationwide study

Molecular mechanisms of action of anti-TNF-α agents – Comparison among therapeutic TNF-α antagonists

Population Pharmacokinetics of Ozoralizumab in Patients with Rheumatoid Arthritis

Antiphospholipid syndrome autoantibodies induction after treatment with anti-TNF alpha therapy in patients with IBD

Disseminated tuberculosis after anti-TNF alpha treatment: Do not blindly trust the IGRA test

Certolizumab pegol for the treatment of chronic plaque psoriasis: Results through 48 weeks from 2 phase 3, multicenter, randomized, double-blinded, placebo-controlled studies (CIMPASI-1 and CIMPASI-2)

Facteurs associés à la rémission sans traitement à 5 ans dans la spondylarthrite axiale débutante : données de la cohorte DESIR

Suchergebnisse filtern